Immunotherapy in Colorectal Cancer: A Promising Avenue?
Danielle Hebert BS#, Kayla Flewelling BS#, Najiha Farooqi MD & Mohamed Kamel, K. MD*
Department of General Surgery, Central Michigan University College of Medicine, MI, USA
Dr. Mohamed Kamel, K., Department of General Surgery, Central Michigan University College of Medicine, MI, USA.
Keywords: Immunotherapy; Cancer; Inhibitors
Advancements in immunotherapy, particularly immune checkpoint inhibitors, have revolutionized the treatment of metastatic colorectal cancer (mCRC). However, the efficacy of available immunotherapeutic agents is largely limited to tumors with DNA mismatch repair-deficient (dMMR) and/or those with microsatellite instability-high (MSI-H) mCRC. Hence, only a small subset of patients with mCRC can potentially benefit from currently available immunotherapeutic drugs. In this review article, the role and future perspectives of novel immunotherapeutic agents in the management of patients with colorectal cancer will be outlined.
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).